This content is only available as a PDF.

Author notes

Source of Support: Funded in part by National Cancer Institute grant P30 CA023100 (MN).

Competing Interests

Conflict of Interest: Mina Nikanjam reports ownership of Genentech stock. Shumei Kato reports the following: consultant for Foundation Medicine, NeoGenomics, and CureMatch; speaker's fee from Roche; advisory board member for Pfizer; research funding from ACT Genomics, Sysmex, Konica Minolta, and OmniSeq. Razelle Kurzrock reports the following: stock and other equity interests in IDbyDNA, CureMatch, Inc., and Soluventis; consulting or an advisory role at Gaido, LOXO, X-Biotech, Actuate Therapeutics, Roche, NeoMed, Soluventis, Pfizer, and Merck; speaker's fees from Roche; research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta, DeBiopharm, Boerhringer Ingelheim, and OmniSeq (all institutional); board member at CureMatch, Inc. and CureMetrix, Inc.

This work is published under a CC-BY-NC-ND 4.0 International License.

Article PDF first page preview

Article PDF first page preview